IQVIA (IQV) Competitors $190.99 +5.60 (+3.02%) Closing price 03:59 PM EasternExtended Trading$190.02 -0.96 (-0.50%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IQV vs. BRKR, ICLR, MEDP, TECH, A, CRL, DHR, MTD, TMO, and WATShould you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include Bruker (BRKR), Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), Charles River Laboratories International (CRL), Danaher (DHR), Mettler-Toledo International (MTD), Thermo Fisher Scientific (TMO), and Waters (WAT). IQVIA vs. Its Competitors Bruker Icon Medpace Bio-Techne Agilent Technologies Charles River Laboratories International Danaher Mettler-Toledo International Thermo Fisher Scientific Waters IQVIA (NYSE:IQV) and Bruker (NASDAQ:BRKR) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Does the media refer more to IQV or BRKR? In the previous week, IQVIA had 28 more articles in the media than Bruker. MarketBeat recorded 39 mentions for IQVIA and 11 mentions for Bruker. Bruker's average media sentiment score of 1.24 beat IQVIA's score of 0.94 indicating that Bruker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 23 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IQV or BRKR? IQVIA currently has a consensus target price of $228.62, indicating a potential upside of 19.70%. Bruker has a consensus target price of $51.30, indicating a potential upside of 44.34%. Given Bruker's higher possible upside, analysts plainly believe Bruker is more favorable than IQVIA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IQVIA 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.74Bruker 0 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.45 Is IQV or BRKR more profitable? IQVIA has a net margin of 7.88% compared to Bruker's net margin of 2.31%. IQVIA's return on equity of 30.05% beat Bruker's return on equity.Company Net Margins Return on Equity Return on Assets IQVIA7.88% 30.05% 6.77% Bruker 2.31%17.89%5.38% Do insiders and institutionals have more ownership in IQV or BRKR? 89.6% of IQVIA shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 1.6% of IQVIA shares are owned by insiders. Comparatively, 27.3% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, IQV or BRKR? IQVIA has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Which has stronger valuation and earnings, IQV or BRKR? IQVIA has higher revenue and earnings than Bruker. IQVIA is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIQVIA$15.41B2.11$1.37B$6.9127.64Bruker$3.44B1.57$113.10M$0.5268.35 SummaryIQVIA beats Bruker on 12 of the 16 factors compared between the two stocks. Get IQVIA News Delivered to You Automatically Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IQV vs. The Competition Export to ExcelMetricIQVIAMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$32.47B$7.05B$5.82B$21.16BDividend YieldN/A1.30%3.84%3.59%P/E Ratio27.6427.1631.1529.14Price / Sales2.11145.24474.7754.98Price / Cash11.5621.6837.1523.84Price / Book5.616.869.115.45Net Income$1.37B$176.42M$3.26B$992.10M7 Day Performance-0.10%0.58%2.12%2.62%1 Month Performance1.65%-0.45%5.13%2.51%1 Year Performance-22.04%13.07%31.25%13.06% IQVIA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IQVIQVIA4.8999 of 5 stars$190.99+3.0%$228.62+19.7%-25.0%$32.47B$15.41B27.6488,000Short Interest ↓BRKRBruker4.9671 of 5 stars$30.78+1.2%$51.30+66.7%-48.0%$4.67B$3.37B59.1911,396ICLRIcon4.2934 of 5 stars$159.71+0.8%$219.54+37.5%-45.6%$12.90B$8.28B16.4341,900Analyst ForecastMEDPMedpace4.3619 of 5 stars$449.77+3.6%$406.60-9.6%+14.6%$12.63B$2.11B33.445,900Positive NewsInsider TradeTECHBio-Techne4.8183 of 5 stars$50.15-0.5%$69.42+38.4%-25.7%$7.86B$1.22B109.023,100Positive NewsDividend AnnouncementAnalyst UpgradeAAgilent Technologies4.8856 of 5 stars$114.22-0.3%$139.77+22.4%-16.3%$32.45B$6.51B28.2017,900News CoveragePositive NewsUpcoming EarningsCRLCharles River Laboratories International4.0618 of 5 stars$148.75+0.0%$175.69+18.1%-24.3%$7.32B$4.05B-111.8420,100News CoveragePositive NewsInsider TradeDHRDanaher4.7346 of 5 stars$199.83-0.4%$247.61+23.9%-24.7%$143.09B$23.88B42.5263,000Positive NewsMTDMettler-Toledo International4.0316 of 5 stars$1,258.27+0.2%$1,288.89+2.4%-10.8%$25.92B$3.87B31.8617,300Positive NewsAnalyst ForecastInsider TradeTMOThermo Fisher Scientific4.9385 of 5 stars$462.59+0.4%$593.00+28.2%-20.8%$174.68B$43.21B26.75125,000Trending NewsInsider TradeAnalyst RevisionWATWaters4.8369 of 5 stars$279.72-0.5%$378.73+35.4%-13.8%$16.65B$3.05B25.227,600 Related Companies and Tools Related Companies Bruker Alternatives Icon Alternatives Medpace Alternatives Bio-Techne Alternatives Agilent Technologies Alternatives Charles River Laboratories International Alternatives Danaher Alternatives Mettler-Toledo International Alternatives Thermo Fisher Scientific Alternatives Waters Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IQV) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access